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Type 2 diabetes (T2DM) confers increased risk of endothelial dysfunction, coronary heart disease, and vulnerability to vein graft
failure after bypass grafting, despite glycaemic control. This study explored the concept that endothelial cells (EC) cultured from
T2DMand nondiabetic (ND) patients are phenotypically and functionally distinct. Cultured human saphenous vein- (SV-) ECwere
compared between T2DM and ND patients in parallel. Proliferation, migration, and in vitro angiogenesis assays were performed;
western blotting was used to quantify phosphorylation of Akt, ERK, and eNOS. The ability of diabetic stimuli (hyperglycaemia,
TNF-𝛼, and palmitate) to modulate angiogenic potential of ND-EC was also explored. T2DM-EC displayed reduced migration
(∼30%) and angiogenesis (∼40%) compared with ND-EC and a modest, nonsignificant trend to reduced proliferation. Significant
inhibition of Akt and eNOS, but not ERK phosphorylation, was observed in T2DM cells. Hyperglycaemia did not modify ND-EC
function, but TNF-𝛼 and palmitate significantly reduced angiogenic capacity (by 27% and 43%, resp.), effects mimicked by Akt
inhibition. Aberrancies of EC function may help to explain the increased risk of SV graft failure in T2DM patients. This study
highlights the importance of other potentially contributing factors in addition to hyperglycaemia that may inflict injury and long-
term dysfunction to the homeostatic capacity of the endothelium.
1. Introduction
The prevalence of type 2 diabetes (T2DM) is increasing glob-
ally with approximately 3.2 million patients in the UK alone,
plus a further 630,000 patients undiagnosed [1]. The leading
cause of mortality in such patients is cardiovascular disease
(CVD) [2], with T2DMpatients suffering a threefold increase
in CVD mortality over those without diabetes [3]. Insulin
resistance is a feature of prediabetes, a silent condition that is
difficult to diagnose early due to compensatory hyperinsuli-
naemia that can maintain glycaemia and delay diagnosis of
the disease. Accordingly, over 30%of newly diagnosed T2DM
patients present with cardiovascular complications [4] the
treatment of which places a significant burden and inevitable
impact on healthcare costs.
Hyperglycaemia is the hallmark of diabetes and clinical
trials have revealed that intensive glycaemic control can ame-
liorate the microvascular complications of T2DM. However,
macrovascular complications persist at least in the medium
term, particularly in patients with active coronary heart
disease [5, 6], suggesting that factors other than glycaemia
may contribute to persistent vascular dysfunction. T2DM
patients frequently present with a variety of metabolic dis-
turbances such as hyperinsulinaemia, inflammation (elevated
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inflammatory cytokines such as tumor necrosis factor alpha;
TNF-𝛼), and disturbed lipid profile (elevated free fatty acids,
e.g., palmitate) that may have a cumulative effect and impart
persistent pathological changes on EC that are not easy to
reverse [7].
The endothelium is a highly metabolic monolayer of cells
that lines the luminal surface of all blood vessels and is a
principal moderator of vascular health (reviewed in [7]).
However, endothelial dysfunction is perceived to precede
the development of overt CVD. In health, the endothelium
maintains a fine balance of secreted factors that maintain
vascular homeostasis. However, in prediabetic patients with
insulin resistance this balance is disturbed and favours
prothrombotic and vasoconstrictive effects [7].
Endothelial dysfunction predisposes patients to athero-
sclerosis and coronary artery disease; thus revascularisation
procedures are almost a requirement in diabetic patients
[8, 9]. The principal method of revascularisation is coronary
artery bypass grafting (CABG), frequently performed using
the autologous long saphenous vein (SV) to bypass diseased
coronary arteries.During SVharvesting, the endothelial layer
is damaged; therefore the ability of endothelial cells (EC) to
proliferate and migrate is essential to restore homeostasis.
Migration of EC is also vital for angiogenesis and the
formation of collateral blood vessels, which provide alternate
pathways of blood flow in the damaged coronary circulation.
Whilst premature coronary artery disease is evident in
T2DM patients, these individuals also suffer inferior out-
comes post-CABG [10, 11]. One particular study showed that
failure of SV grafts occurred in 9.7% of nondiabetic patients
1-year post-CABG, which increased to 14.4% in the diabetic
group [12]. Whilst bypass graft failure is multifactorial,
endothelial dysfunction is certainly a key factor. It is likely
that the impaired capacity of EC to proliferate and migrate is
at least partly due tometabolic disturbances in these patients.
The aims of this study were twofold; firstly, to examine the
in vitro phenotype and function of SV-EC from patients with
or without T2DM, and secondly to investigate the effects of
candidate “diabetic” stimuli on nondiabetic (ND) endothelial
function.
2. Methods
2.1. SV-EC Isolation and Culture. Samples of undistended
SV were collected from patients undergoing coronary artery
bypass grafting at the Leeds General Infirmary. Local ethical
committee approval and informed patient consent were
obtained. The study conformed to the principles outlined
in the Declaration of Helsinki. SV-EC were isolated using
Worthington Type II collagenase digestion (1mg/mL, Lorne
Laboratories, Berkshire, UK) as we described previously [13].
Cells were maintained in M199 medium (Sigma-Aldrich,
Dorset, UK) supplemented with 20% foetal calf serum (FCS;
Labtech International, Sussex, UK), 1% L-glutamine, 1%
antibiotic, 20mM HEPES (all Life Technologies, Paisley,
UK), 15 𝜇g/mL endothelial cell growth supplement, 1𝜇M
pyruvate (both Sigma-Aldrich), and 5U/mL heparin (LEO
Laboratories Ltd., Hurley, UK) in a humidified atmosphere
of 5% CO
2
in air at 37∘C and passaged using trypsin/EDTA
(Life Technologies) as necessary. Endothelial phenotype was
confirmed by positive staining for von Willebrand factor.
All experiments were performed on early passage cells (p3–
7) from patients with (T2DM-EC) or without (ND-EC)
diabetes. All T2DM patients were receiving oral therapies
alone or supplemented with insulin.
2.2. Morphology. Subconfluent SV-EC monolayers were
imaged at ×100 magnification and spread cell areas measured
from 50 cells per patient population as previously described
[14]. In addition, cell circularity was measured using ImageJ
software (http://imagej.nih.gov/ij/) and expressed relative to
a perfect circle with a value of 1.0.
2.3. Proliferation. SV-EC were seeded at a density of 2 × 104
cells per well in 12-well plates and proliferation assays per-
formed essentially as previously described [15, 16]. Following
overnight quiescence in minimal medium (MM; containing
1% FCS), cells were reexposed to medium containing 20%
FCS (designated “day 0”) for up to 5 days, with medium
replenished on day 3. Viable cells were counted on days 0,
3, and 5 using a haemocytometer and trypan blue (Sigma-
Aldrich). Further experiments were performed using a range
of FCS concentrations (5–20%) and all cell counts made on
day 5. Data were expressed as both a percentage increase in
cell number (where day 0 counts = 100%) and area under
curve (AUC).
To examine SV-EC proliferation/death in real time, time-
lapse ptychography [17] was used. Cells were seeded at a
density of 7.5 × 104 cells per well in glass-bottomed 6-
well plates. After overnight quiescence in MM, cells were
reexposed to medium containing 20% FCS for 3 d and
maintained in a humidified environment of 5% CO
2
in air at
37∘C in an incubator surrounding a Phase Focus Virtual Lens
(PFVL21) microscope. Images were acquired as described
previously [18]. Briefly a 20x objective (na 0.4) and a 635 nm
illumination were used to obtain a 0.2mm2 region at the
centre of the dish. Images were acquired every ∼30min for
3 d and used to create a time-lapse video. Finally, these cells
were trypsinised and viability wasmeasured using a Beckman
Coulter Vi-CELL.
2.4. ScratchWoundMigration. Migration was analysed using
a linear scratch wound model essentially as we previously
described [15, 16]. Briefly, confluent SV-EC monolayers were
quiesced in MM for 24 h, wounded with a sterile 10mL
pipette tip to generate a cell free area, imaged, and treated
with medium containing FCS (1–20%) for 24 h after which
the number of cells migrated into the wounded area was
quantified. Data are represented as percentage increase in
migration (versus 1% FCS media (MM) = 100%).
2.5. Signalling. Cells were quiesced in MM for 16 hours
before preparing whole cell lysates and immunoblotting as
previously described [19]. Antibodies were used at the follow-
ing concentrations: phospho-eNOS (Ser1177, BD Biosciences,
1 : 800), phospho-Akt (Ser473, Cell Signaling Technology,
1 : 500), phospho-ERK1/2 (Thr202 and Tyr204, Cell Signaling
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Technology, 1 : 800), total Akt (Cell Signaling Technology,
1 : 500), total ERK (Cell Signaling Technology, 1 : 1000),
and glyceraldehyde 3-phosphate dehydrogenase (GAPDH;
AbCam, 1 : 4000). Films were scanned using an Epson
Perfection 4490 flatbed scanner and densitometry analysis
performed using ImageJ software (http://imagej.nih.gov/ij/).
Data are expressed as a percentage of a “control” lysate
(designated as 100%) that was loaded on all membranes to
allow comparison between experiments. In additional exper-
iments, cells were stimulated with 100 nM insulin (Sigma-
Aldrich) for 5min and lysates were immunoblotted for p-Akt
and p-ERK.
2.6. Angiogenesis. In vitro angiogenesis was investigated
using Matrigel (VWR International, Lutterworth, UK) tube-
forming assays. Briefly, 1 × 105 SV-EC were seeded in MM
in duplicate wells onto polymerised Matrigel 24-well plates.
Plates were incubated at 37∘C in a humidified chamber with
5% CO
2
in air for up to 24 h. The number of intact tubes
was counted in ten random ×100 fields by two independent
observers. In further experiments, SV-EC were pretreated
with either Akt inhibitor LY294002 (1 𝜇M; Merck-Millipore,
Watford, UK), eNOS inhibitor (L-NG-nitroarginine methyl
ester, L-NAME; 500 𝜇M; Sigma-Aldrich), high glucose
(25mM; Sigma-Aldrich), TNF-𝛼 (1 ng/mL; Life Technolo-
gies), palmitate (100 𝜇M; Sigma-Aldrich), or appropriate
control vehicle for 24 h prior to angiogenesis assays. Cells
were incorporated into assays without replenishment of the
stimulus/inhibitor and tube formation was quantified after
8 h.
In selected experiments, time-lapse ptychography [17]
was performed in order to visualise any differences in
ND and T2DM tube dynamics, for example, the rate of
formation or breakdown. In those experiments, cells were
plated on Matrigel-coated glass-bottomed 35mm dishes and
maintained in a humidified environment in 5% CO
2
(in air)
at 37∘C by an incubator surrounding the PFVL21microscope.
Images were acquired as described previously [18]; briefly a
10x objective (na 0.3) and a 635 nm illumination were used
to obtain a 5.88mm2 region at the centre of the dish. Image
acquisition began 2 h after seeding of the cells, taken every
10min for a total period of 24 h and used to create a time-
lapse video such that tube formation and degradation could
be monitored.
2.7. Rhodamine Phalloidin Immunofluorescence. SV-EC were
seeded in gelatin-coated chamber slides at a density of 1 ×
10
4 cells per well, cultured for 72 h in complete growth
medium then fixed in 4% paraformaldehyde. To determine
effects of “diabetic” stimuli, cells were quiesced in MM
and then incubated in medium containing 5% FCS, either
alone or supplemented with high glucose (25mM), TNF-𝛼
(1 ng/mL), palmitate (100 𝜇M), or appropriate controls for
24 h before fixing. The F-actin cytoskeleton was visualised
using fluorescent rhodamine phalloidin (Life Technologies)
as previously described [20]. All images were captured on a
Zeiss Axio Imager Z1 epifluorescencemicroscope at×200 and
×400 magnification.
2.8. Statistics. All data are expressed as mean ± SEM, with 𝑛
representing the number of experiments on cells from differ-
ent patients. Data were analysed using standard or ratio (log
transformed) two-way ANOVA or Mann-Whitney 𝑡-test as
appropriate, using GraphPad software (www.graphpad.com),
with 𝑃 < 0.05 considered statistically significant.
3. Results
3.1. Population Demographics. Experiments were performed
on endothelial cells from a total of 44 patients. The mean
age of ND and T2DM patients was not significantly different:
ND (𝑛 = 27, 85% male), 64.5 ± 1.6 (range 50–80) years
versus T2DM (𝑛 = 17, 82% male), and 67.0 ± 2.1 (range 48–
78) years; 𝑃 = 0.35. All T2DM patients were receiving oral
therapy (metformin/sulfonylureas/gliptins), and 30%of these
were also receiving insulin. Routine cardiovascular medi-
cations (statins, 𝛽-blockers, angiotensin modulating agents,
anticoagulation therapies, and diuretics) were similar in both
cohorts as we have reported previously [21].
3.2. SV-EC Morphology. In contrast to the distinct morpho-
logical and proliferative changes we have previously observed
in SV smooth muscle cells (SV-SMC) from T2DM patients
[14, 21, 22], there were no distinct differences in morphology
between ND and T2DM-EC, with all cells exhibiting a typical
EC cobblestone appearance and no consistent difference in
F-actin organisation (Figure 1(a)). Whilst there was inherent
variability in cell size between patients, this was not associ-
ated with T2DM (Figure 1(b)). Neither did “circularity” vary
between the two populations (Figure 1(c)).
3.3. SV-EC Proliferation. Following SV bypass grafting,
denuded endothelium regenerates through proliferation and
migration. Proliferation was monitored by constructing
growth curves over a 5-day period. Although cell number of
T2DM EC was ∼70% of ND-EC cell number at day 5, this
did not reach statistical significance (Figure 1(d)). Area under
curve analysis for each cell population, whilst suggesting
a trend towards reduced proliferation in the T2DM cells,
did not reach statistical significance (Figure 1(e)). A similar
degree of T2DM-EC proliferative impairment was visible
across a range of concentrations of FCS (Figure 1(f)).
Ptychography [17] is a novel label-free methodology that
generates high quality/contrast phase images of living cells
with no invasive labelling protocols or requirement for high
energy illumination.The ability to digitally focus images after
acquisition prevents loss of data due to focal drift of the
microscope [18]. ND and T2DM-EC were monitored for 3 d
and a quantitative parameter related to cellular dry mass was
calculated at each time point as a measure of proliferation.
Growth profiles of the 3 cell populations for both ND and
T2DM cells over time are represented in Figure 1(g) (left
panel). Video data (Suppl. Files 1 and 2 in Supplementary
Material available online at http://dx.doi.org/10.1155/2015/
409432) show that any reduction in dry mass was due to
cells moving out of the field of view and not to increased cell
death. Two populations (one each of ND and T2DM-EC) did
not proliferate readily, highlighting the inherent interpatient
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Figure 1: SV-EC morphology and proliferation. (a) Morphology of ND and T2DM populations in culture, scale bar = 100 𝜇m. Left-hand
panels = representative phase images from two ND and two T2DM-EC, right-hand panels = rhodamine phalloidin staining of F-actin
cytoskeleton at ×400magnification from one ND and one T2DM-EC population. (b) Spread cell area and (c) mean circularity (roundness) of
50 cells per population of ND and T2DM-ECweremeasured using ImageJ (both 𝑛 = 10, ns = not significant). (d) Proliferation was quantified
by direct counting of live cells over 5 days in full growth medium. Data are expressed as the percentage increase in cell number from day 0
count and (e) area under curve (AUC) (𝑛 = 11, ns = not significant). (f) SV-EC were treated with 5–20% FCS and viable cells counted on day
5. Data is presented as box-and-whiskers with the median indicated (𝑛 = 6-7, ns = not significant). (g) Cells from three ND and three T2DM
donors were monitored over a period of 3 days in full growth medium on a Phase Focus PFVL21 system and the relative cellular dry mass
plotted over time. Right-hand panel = representative ptychographic images of cells dividing (blue asterisks) and dying (red arrowhead), scale
bar = 200 𝜇m. (h) Cell viability following completion of the ptychographic experiment, 𝑛 = 3, ns = not significant.
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Figure 2: SV-ECmigration. Confluent monolayers were quiesced and then wounded to create a cell-free area. Cells were cultured inmedium
containing 1–20% FCS and images taken at 0 and 24 h. The number of cells migrated past the wound edge were counted. (a) Concentration
response to FCS, expressed relative to migration observed in 1% FCS (𝑛 = 9, ∗∗∗𝑃 < 0.001, ∗∗𝑃 < 0.01, ns = not significant relative to 1%
migration). (b) Summary data of migration in media containing 10% FCS (𝑛 = 9, ∗𝑃 < 0.05). (c) Representative images, scale bar = 100 𝜇m.
Cells can clearly be seen migrating past the wound edge at 24 h.
variability as shown by direct cell counting (Figures 1(d)–
1(f)). Importantly, the viability of all cell populations was
similar between ND and T2DM patients (96.2% and 96.8%,
resp.; Figure 1(h)) suggesting that the trend towards reduced
proliferation in T2DM-EC was not a result of increased cell
death. Indeed, time-lapse imaging showed multiple prolifer-
ation events and a lack of cell death events (Figure 1(g), right
panel and Suppl. Files 1 and 2).
3.4. SV-EC Migration. EC motility was assessed using a
scratchwoundmodel where SV-ECmigration into a denuded
area over 24 h (Figure 2(c)) was evaluated. FCS-induced
migration in both ND and T2DM-EC was concentration
dependent, although the response in T2DM-EC was blunted
(Figure 2(a)). Accordingly, in 10% FCS, T2DM-ECmigration
was reduced by >30% compared to ND-EC (Figures 2(b) and
2(c)).
3.5. SV-EC Signalling. It is generally perceived that aberran-
cies of intracellular signalling pathways impact on cellular
function. We therefore explored the concept that basal
differences in two principal insulin-stimulated signalling
pathways, Akt andERK (Figure 3(f)),may be evident between
ND and T2DM SV-EC. Cells were cultured in MM and
phosphorylation of Akt, eNOS, and ERK quantified using
western blotting. Basal phosphorylation states of both Akt
(Figure 3(a)) and eNOS (Figure 3(b)) were significantly lower
in T2DM-EC (56% and 73% of ND-EC, resp.). In contrast,
phosphorylation of ERK was similar in each population
(Figure 3(c)). Diminished Akt phosphorylation in T2DM
cells was maintained in response to stimulation with insulin
(Figure 3(d)) whilst levels of ERK phosphorylation were
similar between populations (Figure 3(e)).
3.6. SV-EC In Vitro Angiogenesis. Patients with T2DM have
impaired ability to form collateral blood vessels [23]; it
is likely that the reduced migratory capacity is a factor
contributing to inferior angiogenesis. Using in vitro tube-
forming assays, time courses were performed, revealing that
the temporal profile of tube formation was similar in ND-
EC and T2DM-EC. However, whilst each SV-EC population
exhibited a similar temporal profile of tube formation which
was maximal after 8 h, the number of tubes was significantly
fewer in theT2DMgroup (∼60%ND) (Figures 4(a) and 4(b)).
To explore the kinetics of tube formation, we performed
time-lapse ptychography over a 24 h interval. The establish-
ment of tube-like networks was evident in both ND-EC and
T2DM-EC after 2 h, the earliest time point at which the
technique could detect all cells within the same plane. In
ND-EC, tubes gradually expanded over the 24 h and formed
stable, robust walls comprised of multiple cell layers (denoted
by red bars in Figure 4(c); also see Suppl. File 3). In T2DM-EC
tubes appeared to expand more rapidly than ND-EC (Suppl.
File 4) but tube walls appeared fragile (generally only one
cell thick) and there were frequent broken/incomplete tubes
(illustrated by asterisks in Figure 4(c)).
T2DM-EC exhibited marked reduction in basal levels of
Akt and eNOS phosphorylation (Figure 3). To determine
whether inhibiting Akt or eNOS activity modulated in vitro
angiogenesis, we treated ND-EC with appropriate inhibitors
(LY294002 and L-NAME, resp.) prior to tube-forming assays.
Exposure to 1 𝜇MLY294002 for 24 h resulted in a reduction in
Akt phosphorylation confirming the efficacy of the inhibitor
in these experiments (Figure 4(d)). Akt inhibition signifi-
cantly impaired tube forming by 36% (Figure 4(e)); however
the effect of L-NAME was inconsistent between cells from
different patients (Figure 4(e)).
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Figure 3: Intracellular signalling in SV-EC. Cells were quiesced in MM (1% FCS) for 16 h and cell lysates immunoblotted for basal
phosphorylation of (a) Akt, (b) eNOS, and (c) ERK. Data was normalised to a control lysate included on every blot and presented as box-
and-whiskers with the median line indicated (upper panel), ∗∗𝑃 < 0.01, ∗𝑃 < 0.05, ns = not significant. Lower panels = representative
western blots. Sensitivity to insulin was determined by treating quiesced cells with 100 nM insulin for 5min. Cell lysates were immunoblotted
for phosphorylation of (d) Akt and (e) ERK; ∗𝑃 < 0.05, ns = not significant. Lower panels = representative western blots showing basal
phosphorylation and in response to insulin. (f) Simplified diagram of the insulin signalling pathway. P = phosphorylation.
3.7. Effects of “Diabetic” Stimuli. ND-ECwere cultured under
conditions designed to mimic the in vivo environment of
T2DM and the impact on angiogenesis assays was evaluated.
We also examined the F-actin cytoskeleton due to its impor-
tant role in migration and intercellular communication [24].
Surprisingly, 25mM glucose had no impact on tube forma-
tion or the cytoskeleton (Figures 5(a) and 5(b)). In contrast,
both the proinflammatory cytokine TNF-𝛼 and free fatty acid
palmitate significantly impaired angiogenesis, by 27% and
43%, respectively (Figures 5(c) and 5(e)). There was reduced
F-actin staining intensity and reorganisation from peripheral
fibres in control cells to more centrally aligned stress fibres
in the TNF-𝛼-treated cells (Figure 5(d)). In palmitate treated
cells a similar reduction in staining intensity was observed
and althoughperipheral localisationwasmaintained, fibres in
the body of the cell appearedmore disorganised (Figure 5(f)).
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Figure 4: SV-EC angiogenesis. Angiogenesis assays were performed by seeding EContoMatrigel and quantifying the number of tubes formed
over time. (a) The number of intact tubes in 10 fields per population (×100 magnification) were quantified over 4–24 h by two independent
observers (𝑛 = 4). (b) Number of intact tubes formed after 8 h (𝑛 = 7, ∗∗𝑃 < 0.01) with representative images using the Phase Focus Virtual
Lens (PFVL21). Scale bar = 500 𝜇m. (c) Enlarged images showing the same field over extended time course.Thewidth of tubewalls is indicated
by a red bar, and breakage of walls is indicated by blue asterisks (scale bar = 250𝜇m). (d) Cells were exposed to 1 𝜇M LY294002 for 24 h and
lysates were immunoblotted for phosphorylation of Akt. (e) ND-EC were treated with 1𝜇M LY294002 for 24 h prior to incorporation into
angiogenesis assays and the number of intact tubes counted (𝑛 = 5, ∗𝑃 < 0.05). (f) Similar experiments were performed after pretreatment
with 500 𝜇M L-NAME or control (D-NAME) (𝑛 = 5, 𝑃 = 0.12).
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Figure 5: Effect of “diabetic” stimuli on SV-EC function. (a) ND-EC were treated with 25mM glucose (with mannitol as osmolarity control)
for 24 h before performing angiogenesis assays and counting the number of intact tubes (𝑛 = 5). (b) Similarly treated cells were fixed and
the F-actin cytoskeleton visualised using rhodamine phalloidin. Scale bars = 50 𝜇m. (c) Parallel assays were performed on cells treated with
1 ng/mL TNF-𝛼 as an inflammatory stimulus ((c, d), 𝑛 = 6, ∗𝑃 < 0.05) and 100 𝜇M palmitate to mimic an elevation in free fatty acids ((e, f),
𝑛 = 6, ∗𝑃 < 0.05).
4. Discussion
A key strength of this study was the use of the exact cells
whose dysfunction underlies failure or complications fol-
lowing bypass grafting in T2DM patients, namely, SV-EC.
During harvesting and grafting for CABG the endothelium is
inevitably denuded and hence EC regeneration through both
proliferation and migration is pivotal to restore a functional
monolayer. In contrast to SV-SMC [14, 21, 22], gross SV-EC
morphology was indistinguishable between ND and T2DM
patients; although this does not rule out the possibility of
subcellular alterations. Instead, we focused on differences in
cellular function that would be viewed as key to cardiovas-
cular health. Importantly, vital functions were persistently
impaired, namely, migration, tube forming, and, to a lesser
degree, proliferation. Lehle et al. previously described a
significant inhibition of proliferation in T2DM-EC isolated
from human SV [25]. Indeed, the difference between the ND
and T2DM cells in our study appears more distinct at later
time points and extending the study beyond 5 days would
potentially answer this question. Importantly, the modest
reduction in T2DM-EC proliferation was not a result of
increased cell death.
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EC migration is also an essential process in reendo-
thelialisation. Indeed, previous studies have demonstrated
impaired migration in bovine [26] and human aortic EC
[27] under conditions of hyperglycaemia, suggesting that the
diabetic milieu may harm the migratory capacity of resident
cells. Studies in a murine model of T2DM also reported
impaired EC migration in the db/db mouse [28]. In human
studies, reduced migration of endothelial progenitor cells
from T2DM patients was impaired relative to ND patients
[28]. Accordingly we observed a significant impairment in
migration of native T2DM-EC relative to ND-EC. Impor-
tantly this divergence was observed under normoglycaemic
conditions (5.5mM glucose), lending credence to the notion
of a persistent EC phenotype imprinted in vivo and that does
not reverse easily in culture.
Insulin signals through the insulin receptor via two main
arms, triggering theAkt andERKpathways [29] (Figure 3(f)).
It is perceived that in T2DM patients the Akt pathway
is impaired with signalling preferentially stimulating the
ERK pathway [7]. To our knowledge this is the first direct
demonstration of divergent Akt and ERK signalling, both
basally and following insulin stimulation, in human SV-EC,
another feature maintained in culture. This is in agreement
with evidence in animal models of diabetes [30] and human
skeletal muscle [31]. Since activation of Akt leads to eNOS
phosphorylation (Figure 3(f)), it is perhaps not surprising
that eNOS phosphorylation was also diminished in T2DM-
EC. Literary evidence for differential eNOS phosphorylation
in T2DM is disparate. Previous studies have revealed reduced
Akt and eNOS phosphorylation in atrial biopsies fromT2DM
patients [32] which concurs with the data presented here;
however phosphorylation of eNOS was reportedly elevated
in venous EC from T2DM patients’ forearms [33]. This
highlights the importance of evaluating the strengths and
weaknesses of different experimental models and advocates
the use of an appropriate cellular model (i.e., SV-EC to
explore dysfunction with respect to graft failure).
An alternative compensatory pathway of restoring blood
flow in arteries diseased by atherosclerosis is the forma-
tion of collateral blood vessels through angiogenic mech-
anisms. These small, new vessels help to revascularise the
myocardium and bypass the occlusion [34]. Given the
increased prevalence of CVD in T2DM patients this is
an important mechanism; however it is well recognised
that such patients suffer from impaired coronary collateral
formation [23] which in turn increases the need for coro-
nary revascularisation. Animal models of diabetes exhibit
reduced angiogenic capacity in vivo [35, 36]. In our study
we used a well validated in vitro model to study SV-EC
angiogenesis and believe this is the first demonstration of
impaired angiogenic capacity in human T2DM-EC versus
ND-EC. Ptychography was used to monitor tube formation
dynamics without damaging or altering the cells, for example,
by using fluorescent labels that potentially interfere with
cell behaviour. This revealed that the initial establishment
of tubes was not different between ND and T2DM-EC;
however T2DM-EC tubes expanded rapidly once established
and exhibited thin, fragile walls that started to degenerate
after 8 h. Combining this knowledge with the reduced total
number of tubes observed at 8 h, it is likely that T2DM-EC
tubes are less stable than ND-EC. Ptychography may be a
useful technique to distinguish between the absolute capacity
to form and maintain robust tubes and the ability to monitor
degeneration. Moreover, the absence of a requirement for cell
“labelling” of any kind, together with a diffuse, low-powered
635 nm illumination, provides confidence that the cell has not
been modified by such markers.
Having observed reduced Akt and eNOS phosphoryla-
tion in native T2DM-EC, we explored whether Akt and/or
eNOS inhibition impaired angiogenesis in EC of nondiabetic
origin. Whilst Akt inhibition significantly reduced tube
formation, the response to eNOS inhibition was inconsis-
tent; four out of six cell populations showing reduced tube
formation to varying degrees. Other downstream effectors
of Akt, for example, vascular endothelial growth factor [37],
may additionally be necessary in order to elicit a significant
and robust inhibition.
Finally, we explored the effects of candidate “diabetic”
stimuli on in vitro angiogenesis. Hyperglycaemia reportedly
impairs EC migration [26, 27] and inhibits angiogenesis in
human microvascular EC [38] and HUVEC [39]. Somewhat
unexpectedlywe observed no effect of consistent high glucose
on angiogenesis in SV-EC, possibly reflecting differences in
the sources of EC. Microvascular and macrovascular EC are
phenotypically distinct [40], and HUVECs express a foetal
gene pattern which is divergent from SV-EC [41]. Another
possible explanation is that variability in glycaemic control is
more deleterious to endothelial cells than persistent hyper-
glycaemia. For example, some previous studies reported that
fluctuating or intermittent high glucose increased expression
of adhesion molecules ICAM-1, VCAM-1, and E-selectin
[42], augmented apoptosis [43], and downregulated NO
production [44]. No studies have investigated hypergly-
caemia per se on human SV-EC angiogenesis but the failure
of intensive glycaemic control to normalise macrovascular
complications in T2DM in the medium term (ACCORD,
ADVANCE, and VADT clinical trials [5, 6]) suggests involve-
ment of other factors.
Circulating levels of TNF-𝛼 are elevated in T2DM
patients [45] but reports of its effects on angiogenesis are
contradictory. TNF-𝛼 inhibits tube-forming in vitro [46] yet
paradoxically increases angiogenesis in vivo [47]. Duration of
exposure to TNF-𝛼 is reportedly key to its pro- or antiangio-
genic effects [48], and dysfunctional angiogenesis has been
attributed to attenuated eNOS activity [49] and modification
of Rho GTPase activity [50]; the latter potentially associated
with disturbed F-actin dynamics as observed in the present
study and previously noted by others [51].
Raised plasma levels of free fatty acids are associated with
metabolic syndrome [52]. Palmitate is proapoptotic to EC
[53, 54] although its effect on angiogenesis is not clear. In
our study, in vitro tube-forming was markedly impaired with
comparatively low (100𝜇M) concentrations of palmitate and
could be attributable to inhibition of eNOS phosphorylation
[53]. Our data also indicate reduced staining intensity of F-
actin and disorganisation of identifiable fibres in palmitate-
treated cells. Palmitate was shown to reduce F-actin content
in L6 myotubes, reportedly via accumulation of membrane
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cholesterol [55]; it is therefore possible that this mechanism
exists in SV-EC.
The “diabetic” stimuli we chose to employ in this study
are neither exclusive nor exhaustive. Multiple cytokines and
chemokines relevant to diabetic complications are induced
by hyperglycaemia, including interleukin-1 beta (IL-1𝛽) [56].
Indeed, hyperglycaemia-induced IL-1𝛽 expression in retinal
endothelial cells is believed to underlie diabetic retinopathy
[57]. Interestingly, a very recent study demonstrated that
monocytes exposed to palmitate secreted IL-1𝛽, which in
turn, induced EC adhesion molecule expression, an effect
abolished by IL-1 receptor antagonism [58]. IL-1𝛽 clearly
plays an important role, both directly and indirectly via effects
on other pathways.
Themaintenance of a persistent aberrant T2DM-EC phe-
notype under culture conditions is perhaps indicative of the
phenomenon of metabolic memory [59]; that is, the concept
that prior exposure to hyperglycaemia and/or other meta-
bolic insults in vivo can lead to maintained cellular effects in
vitro. This is likely to involve epigenetic mechanisms such as
microRNAs, histone modifications and/or DNAmethylation
(reviewed in [7]). Indeed, transient exposure to hypergly-
caemia in human and bovine EC imparted persistent changes
in the nuclear factor kappa B (NF𝜅B) signalling pathway that
were retained even when cells were returned to normogly-
caemia [60, 61]. MicroRNAs (miRs) are short, noncoding
RNAs that negatively regulate target gene expression and
have been proposed as biomarkers for cardiovascular disease
and diabetes [62]. For example, miR-21, widely expressed in
the vasculature, has been reported to inhibit proliferation,
migration, and angiogenesis in HUVEC [63]. It is entirely
possible that similar mechanisms exist in human SV-EC and
studies to investigate this hypothesis are currently in progress.
5. Conclusions
To our knowledge, this study is the first to demonstrate
divergent migration and tube forming capacity in SV-EC
cultured from patients with and without T2DM.There was a
nonsignificant trend towards impaired proliferation. Impor-
tantly we provide direct evidence for selective impairment of
the Akt, but not ERK signalling pathway in these clinically
relevant cells. This T2DM phenotype persisted throughout
culture and passaging, suggestive of epigenetic changes
inflicted in vivo and not easily reversed. ND-EC exposed to
diabetic stimuli adopted a T2DM-EC phenotype, suggesting
the importance of factors other than hyperglycaemia in
promoting endothelial dysfunction in T2DM. In conclusion,
the blunted functionality of SV-EC from T2DM patients in
our study, together with our demonstration that diabetic
stimuli can impair aspects of ND-EC behavior, may translate
into an inadequate or delayed ability to reendothelialise,
significantly impacting the homeostatic capabilities of the
endothelium and predisposing to graft failure.
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